Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...